Indaptus Therapeutics Stock Performance
| INDP Stock | USD 1.80 0.25 16.13% |
The company retains a Market Volatility (i.e., Beta) of 3.69, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Indaptus Therapeutics will likely underperform. At this point, Indaptus Therapeutics has a negative expected return of -0.17%. Please make sure to check out Indaptus Therapeutics' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Indaptus Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Indaptus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Even with latest weak performance, the Stock's fundamental indicators remain invariable and the latest agitation on Wall Street may also be a sign of long-running gains for the enterprise retail investors. ...more
Last Split Factor 1:28 | Dividend Date 2020-10-30 | Last Split Date 2025-06-27 |
1 | Indaptus Therapeutics Chief Scientific Officer Dr. Michael Newman to Present at the Donor Selection Cell Source Summit | 11/17/2025 |
2 | Volume spikes in Indaptus Therapeutics Inc. stock what they mean - Earnings Risk Summary Smart Investment Allocation Insights - newser.com | 11/19/2025 |
3 | Discretionary transaction by Anderson Glen R. of tradable shares of Indaptus Therapeutics subject to Rule 16b-3 | 11/28/2025 |
4 | Navajo Transitional Energy Company Wins Prestigious Sentinels of Safety Award from the National Mining Association | 12/16/2025 |
5 | Acquisition by Jeffrey Meckler of 11187 shares of Indaptus Therapeutics at 5.82 subject to Rule 16b-3 | 12/17/2025 |
6 | Will Indaptus Therapeutics Inc. stock outperform value stocks - Short Setup Weekly High Potential Stock Alerts - DonanmHaber | 12/19/2025 |
7 | Insider Trading | 12/22/2025 |
8 | Indaptus Therapeutics Initial Statement of Beneficial Ownership - marketscreener.com | 12/23/2025 |
9 | Indaptus Enters Into 6 Million Securities Purchase Agreement with Investor David E. Lazar | 12/29/2025 |
10 | Why did INDP stock gain 12 percent today - MSN | 01/06/2026 |
11 | Acquisition by Natan David of 25000 shares of Indaptus Therapeutics at 2.69 subject to Rule 16b-3 | 01/07/2026 |
12 | Will Indaptus Therapeutics Inc. stock recover faster than market - Fit and Size Notes lightweight options for faster days - ulpravda.ru | 01/09/2026 |
13 | Indaptus Therapeutics enters 6M securities purchase agreement with David Lazar - MSN | 02/02/2026 |
Indaptus Therapeutics Relative Risk vs. Return Landscape
If you would invest 251.00 in Indaptus Therapeutics on November 9, 2025 and sell it today you would lose (71.00) from holding Indaptus Therapeutics or give up 28.29% of portfolio value over 90 days. Indaptus Therapeutics is currently does not generate positive expected returns and assumes 8.9745% risk (volatility on return distribution) over the 90 days horizon. In different words, 80% of stocks are less volatile than Indaptus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Indaptus Therapeutics Target Price Odds to finish over Current Price
The tendency of Indaptus Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 1.80 | 90 days | 1.80 | more than 94.0 |
Based on a normal probability distribution, the odds of Indaptus Therapeutics to move above the current price in 90 days from now is more than 94.0 (This Indaptus Therapeutics probability density function shows the probability of Indaptus Stock to fall within a particular range of prices over 90 days) .
Indaptus Therapeutics Price Density |
| Price |
Predictive Modules for Indaptus Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Indaptus Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Indaptus Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Indaptus Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Indaptus Therapeutics is not an exception. The market had few large corrections towards the Indaptus Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Indaptus Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Indaptus Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.77 | |
β | Beta against Dow Jones | 3.69 | |
σ | Overall volatility | 0.42 | |
Ir | Information ratio | -0.06 |
Indaptus Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Indaptus Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Indaptus Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Indaptus Therapeutics generated a negative expected return over the last 90 days | |
| Indaptus Therapeutics has high historical volatility and very poor performance | |
| Indaptus Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (15.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Indaptus Therapeutics currently holds about 33.01 M in cash with (12.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 36.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Indaptus Therapeutics enters 6M securities purchase agreement with David Lazar - MSN |
Indaptus Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Indaptus Stock often depends not only on the future outlook of the current and potential Indaptus Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Indaptus Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 9.4 M | |
| Cash And Short Term Investments | 5.8 M |
Indaptus Therapeutics Fundamentals Growth
Indaptus Stock prices reflect investors' perceptions of the future prospects and financial health of Indaptus Therapeutics, and Indaptus Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Indaptus Stock performance.
| Return On Equity | -3.18 | ||||
| Return On Asset | -1.31 | ||||
| Current Valuation | (1.8 M) | ||||
| Shares Outstanding | 2.24 M | ||||
| Price To Book | 0.87 X | ||||
| EBITDA | (15.37 M) | ||||
| Net Income | (15.02 M) | ||||
| Cash And Equivalents | 33.01 M | ||||
| Cash Per Share | 4.00 X | ||||
| Total Debt | 84.16 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.18 X | ||||
| Book Value Per Share | 2.81 X | ||||
| Cash Flow From Operations | (12.32 M) | ||||
| Earnings Per Share | (29.03) X | ||||
| Market Capitalization | 3.48 M | ||||
| Total Asset | 7.34 M | ||||
| Retained Earnings | (60.44 M) | ||||
| Working Capital | 3.22 M | ||||
About Indaptus Therapeutics Performance
Assessing Indaptus Therapeutics' fundamental ratios provides investors with valuable insights into Indaptus Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Indaptus Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 49.93 | 44.38 | |
| Return On Tangible Assets | (2.35) | (2.24) | |
| Return On Capital Employed | (3.51) | (3.33) | |
| Return On Assets | (2.35) | (2.24) | |
| Return On Equity | (3.43) | (3.26) |
Things to note about Indaptus Therapeutics performance evaluation
Checking the ongoing alerts about Indaptus Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Indaptus Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Indaptus Therapeutics generated a negative expected return over the last 90 days | |
| Indaptus Therapeutics has high historical volatility and very poor performance | |
| Indaptus Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (15.02 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Indaptus Therapeutics currently holds about 33.01 M in cash with (12.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.0, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Indaptus Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 36.0% of the company shares are held by company insiders | |
| Latest headline from news.google.com: Indaptus Therapeutics enters 6M securities purchase agreement with David Lazar - MSN |
- Analyzing Indaptus Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Indaptus Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Indaptus Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Indaptus Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Indaptus Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Indaptus Therapeutics' stock. These opinions can provide insight into Indaptus Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Indaptus Stock Analysis
When running Indaptus Therapeutics' price analysis, check to measure Indaptus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Indaptus Therapeutics is operating at the current time. Most of Indaptus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Indaptus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Indaptus Therapeutics' price. Additionally, you may evaluate how the addition of Indaptus Therapeutics to your portfolios can decrease your overall portfolio volatility.